A chronic low dose of Δ9 tetrahydrocannabinol (THC) restores cognitive function in old mice Andras Bilkei-Gorzo, Onder Albayram, Astrid Draffehn, Kerstin Michel, Anastasia Piyanova, Hannah Oppenheimer, Mona Dvir-Ginzberg, Ildiko Rácz, Thomas Ulas, Sophie Imbeault, Itai Bab, Joachim L Schultze & Andreas Zimmer Nature Medicine, 2017, 23, 782-787. DOI : 10.1038/nm.4311 Abstract : The balance between detrimental, pro-aging, often stochastic processes and counteracting homeostatic mechanisms largely determines the progression of aging. There is substantial evidence suggesting that the endocannabinoid system (ECS) is part of the latter system because it modulates the physiological processes underlying aging. The activity of the ECS declines during aging, as CB1 receptor expression [...]
Lire la suiteSafety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia : An-Open Label, Add-On, Pilot Study Shelef A., Barak Y., Berger U., Paleacu D., Tadger S., Plopsky I., Baruch Y. Journal of Alzheimer's Disease, 2016, 51, 1, 15-19. DOI: 10.3233/JAD-150915 BACKGROUND : Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD). OBJECTIVE : To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD). METHODS : Eleven AD patients were recruited to an open label, 4 weeks, prospective trial. RESULTS : Ten patients completed the trial. Significant reduction [...]
Lire la suiteAmyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids Antonio Currais, Oswald Quehenberger, Aaron M Armando, Daniel Daugherty, Pam Maher and David Schubert NPJ, Aging and Mechanisms of Disease, 2016, 2, 16012; doi:10.1038/npjamd.2016.12; published online 23 June 2016 Nature Partner Journals; www.nature.com/npjamd Abstract : The beta amyloid (Aβ) and other aggregating proteins in the brain increase with age and are frequently found within neurons. The mechanistic relationship between intracellular amyloid, aging and neurodegeneration is not, however, well understood. We use a proteotoxicity model based upon the inducible expression of Aβ in a human central nervous system nerve cell line to characterize a distinct form of nerve [...]
Lire la suitePrenatal cannabis exposure - The “first hit” to the endocannabinoid system Kimberlei A. Richardson, Allison K. Hester, Gabrielle L. McLemore Neurotoxicology and Teratology, 2016, 58, 5-14. DOI : 10.1016/j.ntt.2016.08.003 © 2016 Elsevier Inc. All rights reserved Abstract : As more states and countries legalize medical and/or adult recreational marijuana use, the incidences of prenatal cannabis exposure (PCE) will likely increase. While young people increasingly view marijuana as innocuous, marijuana preparations have been growing in potency in recent years, potentially creating global clinical, public health, andworkforce concerns. Unlike fetal alcohol spectrumdisorder, there is no phenotypic syndrome associated with PCE. There is also no preponderance of evidence that [...]
Lire la suiteConnectome-harmonic decomposition of human brain activity reveals dynamical repertoire re-organization under LSD Selen Atasoy, Leor Roseman, Mendel Kaelen, Morten L. Kringelbach, Gustavo Deco & Robin L. Carhart-Harris Scientific Reports | 7: 17661 | DOI:10.1038/s41598-017-17546-0 www.nature.com/scientificreports Recent studies have started to elucidate the effects of lysergic acid diethylamide (LSD) on the human brain but the underlying dynamics are not yet fully understood. Here we used ’connectome-harmonic decomposition’, a novel method to investigate the dynamical changes in brain states. We found that LSD alters the energy and the power of individual harmonic brain states in a frequency-selective manner. Remarkably, this leads to an expansion of the repertoire [...]
Lire la suitePsychedelic Bibliography Advanced Search https://bibliography.maps.org/default/search
Lire la suiteLSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects Peter Gasser, Katharina Kirchner and Torsten Passie Journal of Psychopharmacology, 2014, 1, 12 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881114555249 jop.sagepub.com Abstract Objective : A recently published study showed the safety and efficacy of LSD-assisted psychotherapy in patients with anxiety associated with lifethreatening diseases. Participants of this study were included in a prospective follow-up. Method : 12 months after finishing LSD psychotherapy, 10 participants were tested for anxiety (STAI) and participated in a semi-structured interview. A Qualitative Content Analysis (QCA) was carried out on the interviews to elaborate about LSD effects and [...]
Lire la suiteSafety and Efficacy of Lysergic Acid Diethylamide-Assisted-Psychotherapy for Anxiety Associated With Life-threatening Diseases Peter Gasser, Dominique Holstein, Yvonne Michel, Rick Doblin, Berra Yazar-Klosinski, Torsten Passie, and Rudolf Brenneisen Journal of Nervous and Mental Diseases, 2014 Abstract : A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with lifethreatening diseases. Treatment included drug-free psychotherapy sessions supplemented by two LSD-assisted psychotherapy sessions 2 to 3 weeks apart. The participants received either 200 Kg of LSD (n = 8) or 20 Kg of LSD with an open-label crossover to 200 [...]
Lire la suiteLSD-Assisted Psychotherapy for Anxiety Related to Life-Threatening Illness Category: LSD-Assisted Psychotherapy: MAPS-Sponsored Clinical Trials Location: Solothurn, Switzerland MAPS is proud to sponsor the first study of the therapeutic use of LSD in humans in over 40 years. This study, based in Switzerland, investigates the safety and effectiveness of LSD-assisted psychotherapy in subjects with life-threatening illnesses and who are experiencing associated anxiety. The study received final approval from the BAG (the Swiss DEA) on December 5, 2007, final approval from the Ethics Committee (the Swiss IRB equivalent) on October 30, 2007, and clearance from SwissMedic (the Swiss FDA equivalent) on November 8, 2007. The [...]
Lire la suiteLSD-Assisted Psychotherapy https://maps.org/research/psilo-lsd MAPS has completed the first double-blind, placebo-controlled study of the therapeutic use of LSD in human beings since the early 1970s. LSD (lysergic acid diethylamide) is a semi-synthetic compound first developed in 1938 by Dr. Albert Hofmann at the Sandoz pharmaceutical company in Basel, Switzerland. After Dr. Hofmann first discovered its effects in 1943, LSD quickly became recognized for its possible therapeutic effects. LSD also played a significant role in the discovery of the serotonin neurotransmitter system. Experimental LSD capsule from our completed Swiss pilot study Our completed Phase 2 pilot study in 12 subjects found positive trends in the reduction of anxiety [...]
Lire la suite